Effects of antithrombin III on tumor necrosis factor-alpha and interleukin-1beta synthesis in vascular smooth muscle cells.
In the course of sepsis, severe coagulopathy and disseminated intravascular coagulation (DIC) are common events. Therefore, substances known to interfere with the coagulation cascade have been studied in animal models of sepsis. Among them, antithrombin III (AT III) was reported to be a promising therapeutic tool because it exhibited anti-inflammatory properties in addition to its anticoagulative effects. In our studies using vascular smooth muscle cells (VSMC) as a monoculture model, contradictory effects of AT III on the release of the proinflammatory agonists tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) were found. Whereas AT III inhibited the lipopolysaccharide (LPS)-induced production of these cytokines on both the transcriptional and the translational levels when given at higher concentrations (5 or 10 U/ml), lower amounts of AT III did not show this suppressive effect. In contrast, 0.5, 1, and 5 U/ml AT III led to an enhancement of TNF-alpha synthesis when combined with LPS. To date, we cannot provide a mechanism to explain the AT III-promoted modulation of TNF-alpha and IL-1beta generation in VSMC. However, with respect to its potential therapeutic benefit in systemic inflammatory conditions, AT III should not be regarded strictly as an anti-inflammatory modulator.
Totzke
G
G
Department of Physiology I, University of Bonn, 53115 Bonn, Germany.
Schobersberger
W
W
Schloesser
M
M
Czechowski
M
M
Hoffmann
G
G
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000990:Antithrombin III / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D007375:Interleukin-1 / Q000096:biosynthesis* / Q000235:genetics; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000276:immunology*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011921:Rats, Inbred WKY; D014158:Transcription, Genetic / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000235:genetics
D000893:Anti-Inflammatory Agents; D007375:Interleukin-1; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D000990:Antithrombin III